<DOC>
	<DOC>NCT00980018</DOC>
	<brief_summary>The purpose of this exploratory study will be to examine changes in chronic low grade chronic adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE) grading, when patients are switched from imatinib to nilotinib therapy.</brief_summary>
	<brief_title>An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1. Male or female patients â‰¥ 18 years of age 2. ECOG 0, 1, or 2 3. Diagnosis of CMLCP associated with BcrAbl quantifiable by RQPCR (IS) 4. Patients must be an imatinib responder and achieved the following efficacy milestones as appropriate for the length of time on imatinib therapy as per protocol 5. CMLCP patients initiated on any dose of imatinib 6. Ability to provide written informed consent prior to any study related screening procedures being done 1. Loss of CHR or cytogenetic response 2. Prior accelerated phase or blast phase CML 3. Previously documented T315I mutation 4. Presence of chromosomal abnormalities (trisomy 8) and/or clonal evolution other than Ph+. 5. Previous treatment with any other tyrosine kinase inhibitor except for imatinib. 6. Treatment with other investigational agents within 30 days of Day 1. 7. History of noncompliance to medical regimens or inability to grant consent. 8. Women who are pregnant, breast feeding, or of childbearing potential without a negative serum test at baseline. Male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following discontinuation of study drug. Postmenopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential. Women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>CML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Tasigna</keyword>
	<keyword>nilotinib</keyword>
	<keyword>AMN107</keyword>
	<keyword>CML-CP</keyword>
	<keyword>Chronic Phase</keyword>
</DOC>